<DOC>
	<DOC>NCT02356562</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ombitasvir/ABT-450/r and dasabuvir with or without Sofosbuvir and RBV in DAA treatment-experienced adults with Genotype 1 Chronic Hepatitis C Virus infection.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Sofosbuvir and RBV in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>history of previous direct acting antiviral (DAA) therapy failure HCV genotype 1 infection Females must be postmenopausal, of nonchild bearing potential or practicing specific forms of birth control Positive screen for hepatitis B surface antigen or antihuman immunodeficiency virus antibody discontinuation of the prior DAA treatment for reasons other than virologic failure confirmed presence of hepatocellular carcinoma abnormal lab tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>